Roger Winkle, MD
Clinical Cardiac Electrophysiology · E Palo Alto, CANPI 1700810330
Payments from drug & device makers
What this record shows
This record is dominated by other: $77,647 of the $77,659 with a category attached, or 100.0%. Boston Scientific accounts for 100.0% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $38,321 and has fallen 56.2% since, to $16,786 in 2024.
Across 7 payments — averaging $11,094 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$78K
- Amgen$12
Across 15 payments — averaging $6068.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$91K
What the payments were for
- Food & beverage$120%
- Other$77,647100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 6 | $77,647 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL EP$52,431
How this compares
$77,659 in reported general payments places this provider in the 75th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $228,372 |
| XareltoRivaroxaban | 38 | $56,615 |
| Repatha SureclickEvolocumab | 21 | $32,201 |
| Dofetilide | 33 | $16,893 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $4,953 |
| Ezetimibe | 105 | $3,476 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 62 | $3,317 |
| Atorvastatin Calcium | 223 | $2,795 |
| Carvedilol | 107 | $1,752 |
| Irbesartan | 28 | $823 |
| Spironolactone | 42 | $697 |
| Enalapril Maleate | 20 | $521 |
| Lisinopril | 28 | $511 |
| Digoxin | 22 | $509 |
| Losartan Potassium | 30 | $499 |
Paid to pharmacies, not to this prescriber.
Other clinical cardiac electrophysiology in E Palo Alto
- Melissa KongE Palo Alto$303K
- Robert MeadE Palo Alto$184K
- Gregory EngelE Palo Alto$105K
- Shephal DoshiSanta Monica$2.1M
- Jonathan HsuSan Diego$1.2M
- Leslie SaxonLos Angeles$1.1M
- Rahul BhardwajLoma Linda$935K
- Nicholas Olsonla Jolla$801K
- Jonathan DukesVentura$775K
- Brett GidneySanta Barbara$756K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.